Day One Biopharmaceuticals, Inc. (ticker: DAWN) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of DAWN's SEC filings surfaces 3 active risk signals, including 2 delisting/deregistration signals, and 1 auditor-change signal. DAWN reported $158.18M in revenue and -$107.32B for the period ending 2025-12-31, with operating cash flow of -$103.76M. Cash and equivalents stood at $197.08M (up 57.7% year-over-year). Total assets of $507.83M exceed total liabilities of $66.67M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
DAWN Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Day One Biopharmaceuticals, Inc. (DAWN) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.